Advancements in MS Treatment: New Gadolinium Agent, Myelin, and High-Efficacy DMTs

A Phase 3 clinical trial will test a new gadolinium-based MRI contrast agent, gadoquatrane, which uses a dose that is 60% lower than other agents, potentially addressing concerns about kidney problems. Research suggests that myelin-coated nerves may be more vulnerable to inflammatory damage than uncoated ones, opening new avenues for multiple sclerosis (MS) treatment. A study recommends starting MS treatment with high-efficacy disease-modifying therapies (DMTs) to achieve better outcomes, challenging the practice of prescribing less-effective DMTs as first-line treatments.